TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04297306

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Prescription
Description: Standardised Exercise Prescription.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise Prescription and Virtual Reality Exercise Gaming support
Description: Standardised Exercise Prescription with the additional support of Virtual Reality Promoted Exercise Games.
Study: NCT02815176

Intervention type: OTHER
Intervention: Blood sampling
Description: Sampling the blood including DNA to investigate the thrombotic profile
Study: NCT00781599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chantix
Description: Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chantix
Description: Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Counseling
Description: Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Counseling
Description: Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Counseling
Description: Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
Study: NCT01403701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: pelvic floor physical therapy
Study: NCT01106625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The patient's stable dose of background metformin therapy should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The patient's stable dose of background metformin therapy should be continued throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: The patient's stable dose of background metformin therapy should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylruea
Description: The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylruea
Description: The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulphonylruea
Description: The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
Study: NCT05271422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Pulse Electrical Stimulation (NuEyne 01)
Description: Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulse Electrical Stimulation
Description: Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
Study: NCT00736866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
Study: NCT02432248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: 75mg/day, PO for 90 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo(medical starch)
Description: 75mg/day, PO for 90 days
Study: NCT00947752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate
Description: Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Glatiramer Acetate
Description: GA 20 mg/0.5 mL
Study: NCT06409091

Intervention type: DEVICE
Intervention: Medium weight or Heavy weight mesh
Description: Patients received a hernia repair with one of the two groups

Intervention type: DEVICE
Intervention: Medium weight or Heavy weight mesh
Description: Patients received a hernia repair with one of the two groups
Study: NCT03489135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReVene Thrombectomy Catheter
Description: Endovascular treatment of an acute iliofemoral DVT
Study: NCT02299245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: different dose of rosuvastatin treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: different dose of rosuvastatin treatment
Study: NCT04260958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation
Description: The exercise program (remote/centre-based) will be standardized. An exCR-program is defined as at least 24 supervised sessions, with a total session length of 60 minutes, for at least 3 months, with possibility to complete missed sessions the 4th month. Each exercise session includes at least 20 min of aerobic exercise, intensity 13-17 on Borg´s rating of perceived exertion (RPE)-scale ≈ 60% - 85% of VO2max or 70 - 95% of maximal heart rate. In addition, each exercise session includes 1-3 sets of 8-10 upper and/or lower limb exercises in 10-15 repetitions, 40-80% of 1 repetition maximum. Attending ≥75% of the 24 sessions over a 4-month period will be considered as successful.
Study: NCT01855984

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral mixed tocotrienols
Description: 200mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
Study: NCT04445909

Intervention type: DEVICE
Intervention: VA-ECMO
Description: Deployment of extracorporeal membrane oxygenation cardiac assist device.
Study: NCT02563015

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: liquid drops
Study: NCT04627298

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educational video game for preteens to support HPV vaccination
Description: An educational video game developed for 11-12 year olds to increase interest in and decision to pursue HPV vaccination.
Study: NCT03378726

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrients
Description: Micronutrient powder is the current supplement provided by the Colombian Ministry of Health and Social Protection to children between 1 and 5 years of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPOON Group Counseling
Description: SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPOON Group Counseling
Description: SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling
Description: SPOON interpersonal counseling is an innovative behavior change strategy in which participants will learn information via one-on-one sessions with the instructor.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SQ-LNS
Description: SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SQ-LNS
Description: SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Counseling
Description: Standard counseling refers to the counseling currently provided by health personnel to women and children in the selected intervention area of Colombia
Study: NCT01260376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
Study: NCT02287441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: Tomato Products (tomato)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Raw
Description: Vegetables Prepared Raw (raw).
Study: NCT03697655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab 20 MG/ML [Darzalex]
Description: Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab 20 MG/ML [Darzalex]
Description: Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
Study: NCT04410510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Et (Caesalpinia spinosa extract)
Description: P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule equivalent to 250mg of excipients of P2Et every 12 hours for 14 days + Standard Care
Study: NCT00712335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: DPI 250 mcg BID for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: DPI 250 mcg BID for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: PO 10 mg QHS for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: PO 10 mg QHS for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: DPI 50mg BID for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: DPI 50mg BID for 3 weeks
Study: NCT01867632

Intervention type: DEVICE
Intervention: Acellular Dermal Matrix
Study: NCT02509585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m tilmanocept
Description: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
Study: NCT03738111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 Citrate
Description: TG02 citrate capsules
Study: NCT03946046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical targeting
Description: The intervention consists of the injection of botulinum toxin A into muscles targeted by a clinical localization method (observation and palpation of target muscles)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography targeting
Description: The intervention consists of the injection of botulinum toxin A into muscles by ultrason-guided method
Study: NCT02607670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAT4 Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Study: NCT03350542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY 48 mm
Description: A drug eluting coronary stent system
Study: NCT03703856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of early auditory information processing memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated.
Study: NCT04010318

Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.

Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
Study: NCT01831284

Intervention type: PROCEDURE
Intervention: Sigmoidoscopy with biopsy
Description: Sigmoidoscopy with biopsy

Intervention type: PROCEDURE
Intervention: Sigmoidoscopy with biopsy
Description: Sigmoidoscopy with biopsy

Intervention type: PROCEDURE
Intervention: Sigmoidoscopy with biopsy
Description: Sigmoidoscopy with biopsy
Study: NCT04470258

Intervention type: OTHER
Group type: OTHER
Intervention: ELMO PROJECT AT COVID-19: STUDY IN HUMANS
Description: The Elmo system will be applied to 10 patients with hypoxemic respiratory failure by COVID-19 and its effectiveness will be assessed by analyzing the physiological variables and the patient's comfort, as well as their clinical outcomes (need for tracheal intubation) and recovery time. Hypoxemic respiratory failure and need for O2.

Intervention type: DEVICE
Group type: OTHER
Intervention: ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY
Description: After testing for the following requirements: offering CPAP, ensuring the maintenance of alveolar ventilation without CO2 rebreathing, monitoring intra-ELMO pressure, minimizing adverse effects of the system such as noise, face temperature, airway dryness and comfort global; tests will be carried out on healthy volunteers using prototypes of the Elmo system and assessing whether their effectiveness in providing positive airway pressure and their usability from the perspective of their primary users (doctor, physiotherapist and nurses) and the volunteer's comfort . With this, realistic simulations will be carried out, centered on the evaluation based on heuristic principles.
Study: NCT00317226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
Study: NCT02238418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol vial (100 000 UI)
Description: VISIT 1:~Patient \> 60 kg and initial 25OHD serum concentration \< 25nmol/L : prescription of 4 vials to be taken every 2 weeks between 25 and 50 nmol/L: prescription of 3 vials to be taken every 2 weeks between 50 and 75 nmol/L: prescription of 2 vials to be taken every 2 weeks Patient between 20 and 60 kg and initial 25OHD serum concentration \< 25nmol/L: prescription of 2 vials to be taken every month between 25 and 50 nmol/L: prescription of 2 vials to be taken every 6 weeks between 50 and 75 nmol/L: prescription of 1 single vial Patient \< 20 kg and initial 25OHD serum concentration \< 75 nmol/L: prescription of 1 single vial~A local lab will performed urinary dosage of calciuria and creatininuria:~* at days 0, 1, 2, 3, 4 and 7 after the first intake of a 25OHD vial~* at days 0, 2 and 4 after other intakes (when applicable)~VISIT 2:~25OHD serum concentration will then be dosed at month 2 after visit 1
Study: NCT00356265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procedure: Regional phenylephrine arterial infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: Regional phenylephrine arterial infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: Regional phenylephrine arterial infusion
Study: NCT01784653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMET
Description: Self-completed, computerized motivational enhancement therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET
Description: Clinician-delivered Motivational Enhancement Therapy
Study: NCT03957213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Acute intermittent hypoxia is a safe, non-invasive technique. All sessions will be monitored by research study staff trained in delivering acute intermittent hypoxia. Hypoxic intervals will be delivered with a commercially available sports performance hypoxicator. A unit capable of delivering a fraction of inspired oxygen ranging from 21%-9% will be used. Air will be delivered into a mask that will be secured comfortably over the subject's nose and mouth. Intervention sessions will occur for 10 days over a 2 week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: 60 minutes of Double Decision cognitive training for 10 days over a 2 week period.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computerized Cognitive Training
Description: 60 minutes of Double Decision cognitive training for 10 days over a 2 week period.
Study: NCT06390826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT02303886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue
Description: In NaCL0.9% 100 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylene blue
Description: In NaCL0.9% 100 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue
Description: in NaCl 0.9% 100 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylene blue
Description: in NaCl 0.9% 100 ml
Study: NCT01096979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-102
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-102
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01220609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03471208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Navigation Assisted Implant Surgery
Description: Implant surgery using dynamic navigation assistance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Freehand Implant Surgery
Description: Dental implant surgery via conventional freehand
Study: NCT00099268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa/entacapone
Description: Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release carbidopa/levodopa
Description: Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
Study: NCT02941510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject(s) will participate in all study activities but will receive placebo.
Study: NCT01754506

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish Oil
Description: EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
Study: NCT02563015

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: liquid drops

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference 400
Description: liquid drops
Study: NCT00793520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Twice daily oral administration of Milnacipran for 5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice daily oral administration of placebo for 5 weeks.
Study: NCT00793520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice daily oral administration of placebo for 5 weeks.